Biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ: ACXP) reported on Monday that it has received further FDA guidance on its ibezapolstat clinical development programme, including the potential for a single Phase 3 trial to support a New Drug Application (NDA) for both treatment and reduction of recurrence of Clostridioides difficile infection (CDI).
Following a Type C meeting on 13 July 2026, the FDA agreed that a successful IBZ-ASPIRE Phase 3 trial, supported by the IBZ-PATHFINDER Phase 2 trial in multiply recurrent CDI, could enable an NDA submission covering both indications.
The planned IBZ-ASPIRE trial will evaluate ibezapolstat against vancomycin in approximately 550 patients using a non-inferiority design. If successful, further analyses will assess superiority for reducing recurrence and improving clinical cure rates.
Acurx has initiated start-up activities for the IBZ-PATHFINDER trial in patients with recurrent CDI, with enrolment expected to begin in the coming months. The Company plans to advance the international Phase 3 IBZ-ASPIRE trial subject to funding availability.
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia